Literature DB >> 24094298

Emerging biomarkers in cognition.

Meredith Wicklund1, Ronald C Petersen.   

Abstract

Knowledge of aging and dementia is rapidly evolving with the aim of identifying individuals in the earliest stages of disease processes. Biomarkers allow clinicians to show the presence of a pathologic process and resultant synapse dysfunction and neurodegeneration, even in the earliest stages. This article focuses on biomarkers for mild cognitive impairment caused by Alzheimer disease, structural magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (PET) or single-photon emission computed tomography, and PET with dopamine ligands. Although these biomarkers are useful, several limitations exist. Several new biomarkers are emerging and a more biological characterization of underlying pathophysiologic spectra may become possible.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Biomarkers; Dementia

Mesh：

Substances：

Year:  2013        PMID： 24094298      PMCID： PMC3968430          DOI： 10.1016/j.cger.2013.07.006

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN： 0749-0690            Impact factor:   3.076


  133 in total

1.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

Review 2.  Mild cognitive impairment.

Authors:  Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

3.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

4.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

5.  Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Authors:  Gaël Chételat; Victor L Villemagne; Kerryn E Pike; Kathryn A Ellis; Pierrick Bourgeat; Gareth Jones; Graeme J O'Keefe; Olivier Salvado; Cassandra Szoeke; Ralph N Martins; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2011-02-09       Impact factor: 13.501

6.  Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Authors:  Magnus Sjögren; Pia Davidsson; Anders Wallin; Ann-Kathrine Granérus; Eva Grundström; Håkan Askmark; Eugeen Vanmechelen; Kaj Blennow
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

7.  Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss.

Authors:  Michelle M Mielke; Norman J Haughey; Veera Venkata Ratnam Bandaru; Steven Schech; Richard Carrick; Michelle C Carlson; Susumu Mori; Michael I Miller; Can Ceritoglu; Timothy Brown; Marilyn Albert; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

8.  CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

Authors:  L Parnetti; A Lanari; S Amici; V Gallai; E Vanmechelen; F Hulstaert
Journal:  Neurol Sci       Date:  2001-02       Impact factor: 3.307

9.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

10.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501
View more
  2 in total

1.  Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference.

Authors:  John E Morley; John C Morris; Marla Berg-Weger; Soo Borson; Brian D Carpenter; Natalia Del Campo; Bruno Dubois; Keith Fargo; L Jaime Fitten; Joseph H Flaherty; Mary Ganguli; George T Grossberg; Theodore K Malmstrom; Ronald D Petersen; Carroll Rodriguez; Andrew J Saykin; Philip Scheltens; Eric G Tangalos; Joe Verghese; Gordon Wilcock; Bengt Winblad; Jean Woo; Bruno Vellas
Journal:  J Am Med Dir Assoc       Date:  2015-09-01       Impact factor: 4.669

Review 2.  Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways.

Authors:  C Bohm; F Chen; J Sevalle; S Qamar; R Dodd; Y Li; G Schmitt-Ulms; P E Fraser; P H St George-Hyslop
Journal:  Mol Cell Neurosci       Date:  2015-03-04       Impact factor: 4.314
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.